United States Biotechnology & Medical Research

Phathom Pharmaceuticals Inc (PHAT)

Track

Insider trading activity at Phathom Pharmaceuticals Inc. has been inactive over the last three months. The most recent transaction occurred on November 3, 2025, involving a sale of shares by the Principal Accounting Officer. Prior to this period, the company saw a mix of buying and selling activity from various executives throughout 2025.
Ticker: PHAT Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Phathom Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 3 Nov 2025
Value US$570,047.08 | Price 339.41 | Shares 3,508 (-14.1%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-11-05 2025-11-03 S Sale
1.5
Breedlove Robert Charles

Principal Accounting Officer

Officer
3,508 -14.1%
339.41
US$570,047 		3,508 -14.1% 339.41 US$570,047
2025-09-09 2025-09-05 S Sale
1.5
Breedlove Robert Charles

Principal Accounting Officer

Officer
33,583 +20.3%
321.13
US$2,240,830 		33,583 +20.3% 321.13 US$2,240,830
2025-07-18 2025-07-16 S Sale
1.5
Breedlove Robert Charles

Principal Accounting Officer

Officer
52,916 -37.8%
414.85
US$3,621,527 		52,916 -37.8% 414.85 US$3,621,527
2025-05-23 2025-05-21 B Purchase
3.7
Topper James N
Non-Executive Director
3,780 +6.8%
3.86
US$14,609 		3,780 +6.8% 3.86 US$14,609
2025-05-15 2025-05-14 B Purchase
3.7
Topper James N
Non-Executive Director
6,300 +12.8%
3.32
US$20,919 		6,300 +12.8% 3.32 US$20,919
2025-05-15 2025-05-13 B Purchase
3.7
Topper James N
Non-Executive Director
1,120 +2.3%
3.16
US$3,543 		1,120 +2.3% 3.16 US$3,543
2025-05-13 2025-05-12 B Purchase
3.7
Topper James N
Non-Executive Director
12,601 +35.4%
3.04
US$38,301 		12,601 +35.4% 3.04 US$38,301
2025-05-13 2025-05-09 B Purchase
3.7
Topper James N
Non-Executive Director
2,226 +6.7%
3.62
US$8,053 		2,226 +6.7% 3.62 US$8,053
2025-05-13 2025-05-09 B Purchase
3.7
Topper James N
Non-Executive Director
33,376 +inf%
3.19
US$106,563 		33,376 +inf% 3.19 US$106,563
2025-05-08 2025-05-07 B Purchase
3.9
Parikh Asit
Non-Executive Director
5,000 +5.5%
2.40
US$11,984 		5,000 +5.5% 2.40 US$11,984
2025-05-08 2025-05-06 B Purchase
3.9
Parikh Asit
Non-Executive Director
5,000 +5.8%
2.60
US$13,000 		5,000 +5.8% 2.60 US$13,000
2025-04-08 2025-04-07 S Sale
3.5
Henderson Molly

CFO and CBO

Officer
3,678 -3.9%
4.55
US$16,740 		3,678 -3.9% 4.55 US$16,740
2025-03-17 2025-03-13 B Purchase
3.9
Parikh Asit
Non-Executive Director
10,000 +13.2%
4.42
US$44,200 		10,000 +13.2% 4.42 US$44,200
2025-01-23 2025-01-21 PlS Planned sale
2.5
Nabulsi Azmi

Chief Operating Officer

Officer
7,886 -3.3%
6.59
US$51,957 		7,886 -3.3% 6.59 US$51,957
2025-01-23 2025-01-21 PlS Planned sale
3.5
Henderson Molly

CFO and CBO

Officer
6,583 -6.6%
6.59
US$43,371 		6,583 -6.6% 6.59 US$43,371
2025-01-23 2025-01-21 PlS Planned sale
3.2
Curran Terrie

President and Chief Executive

Executive Director
19,109 -5.0%
6.59
US$125,884 		19,109 -5.0% 6.59 US$125,884
2024-12-20 2024-12-19 S Sale
2.5
Nabulsi Azmi

Chief Operating Officer

Officer
1,118 -0.5%
8.00
US$8,944 		1,118 -0.5% 8.00 US$8,944
2024-12-20 2024-12-19 S Sale
3.5
Henderson Molly

CFO and CBO

Officer
1,291 -1.3%
8.00
US$10,328 		1,291 -1.3% 8.00 US$10,328
2024-12-16 2024-12-13 B Purchase
3.9
Parikh Asit
Non-Executive Director
10,000 +15.3%
8.12
US$81,248 		10,000 +15.3% 8.12 US$81,248
2024-12-16 2024-12-13 B Purchase
1.2
KARBE FRANK
Non-Executive Director
12,500 +28.1%
7.93
US$99,084 		12,500 +28.1% 7.93 US$99,084
2024-07-17 2024-07-15 PlS Planned sale
3.5
Henderson Molly

CFO and CBO

Officer
4,325 -4.2%
11.72
US$50,689 		4,325 -4.2% 11.72 US$50,689
2024-07-17 2024-07-15 PlS Planned sale
3.2
Curran Terrie

President and Chief Executive

Executive Director
33,848 -8.2%
11.72
US$396,699 		33,848 -8.2% 11.72 US$396,699
2024-07-17 2024-07-15 PlS Planned sale
2.5
Nabulsi Azmi

Chief Operating Officer

Officer
10,901 -4.3%
11.72
US$127,760 		10,901 -4.3% 11.72 US$127,760
2024-04-10 2024-04-08 S Sale
3.5
Henderson Molly

CFO and CBO

Officer
3,435 -3.5%
11.10
US$38,128 		3,435 -3.5% 11.10 US$38,128
2024-03-26 2024-03-22 PlS Planned sale
3.2
Curran Terrie

President and Chief Executive

Executive Director
16,851 -3.9%
9.11
US$153,513 		16,851 -3.9% 9.11 US$153,513
2024-01-25 2024-01-24 S Sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
3,703,703 -49.7%
8.10
US$29,999,994 		3,703,703 -49.7% 8.10 US$29,999,994
2024-01-22 2024-01-19 PlS Planned sale
3.5
Henderson Molly

CFO and CBO

Officer
6,307 -6.0%
7.75
US$48,900 		6,307 -6.0% 7.75 US$48,900
2023-11-21 2023-11-20 S Sale
3.5
Henderson Molly

CFO and CBO

Officer
2,127 -2.0%
7.24
US$15,403 		2,127 -2.0% 7.24 US$15,403
2023-11-08 2023-11-08 B Purchase
3.9
Parikh Asit
Non-Executive Director
2,500 +4.8%
7.80
US$19,500 		2,500 +4.8% 7.80 US$19,500
2023-11-08 2023-11-07 B Purchase
3.9
Parikh Asit
Non-Executive Director
4,000 +8.2%
7.76
US$31,040 		4,000 +8.2% 7.76 US$31,040
2023-11-08 2023-11-06 B Purchase
3.9
Parikh Asit
Non-Executive Director
1,000 +2.1%
8.04
US$8,040 		1,000 +2.1% 8.04 US$8,040
2023-11-03 2023-11-01 S Sale
3.5
Henderson Molly

CFO and CBO

Officer
11,681 -10.0%
8.95
US$104,545 		11,681 -10.0% 8.95 US$104,545
2023-11-03 2023-11-01 S Sale
3.5
Henderson Molly

CFO and CBO

Officer
811 -0.7%
7.80
US$6,326 		811 -0.7% 7.80 US$6,326
2023-06-05 2023-06-02 PlS Planned sale
3.5
Henderson Molly

CFO and CBO

Officer
1,960 -2.8%
11.41
US$22,368 		1,960 -2.8% 11.41 US$22,368
2023-05-23 2023-05-22 PlS Planned sale
3.5
Henderson Molly

CFO and CBO

Officer
2,110 -2.9%
12.87
US$27,165 		2,110 -2.9% 12.87 US$27,165
2023-04-11 2023-04-11 B Purchase
2.5
Nabulsi Azmi

Chief Operating Officer

Officer
10,000 +11.2%
8.26
US$82,600 		10,000 +11.2% 8.26 US$82,600
2023-04-11 2023-04-10 B Purchase
3.9
Parikh Asit
Non-Executive Director
1,000 +4.4%
7.55
US$7,550 		1,000 +4.4% 7.55 US$7,550
2023-04-07 2023-04-06 PlS Planned sale
3.5
Henderson Molly

CFO and CBO

Officer
3,439 -4.5%
7.27
US$25,002 		3,439 -4.5% 7.27 US$25,002
2023-04-07 2023-04-06 B Purchase
3.2
Curran Terrie

President and Chief Executive

Executive Director
12,919 +7.4%
7.82
US$101,025 		12,919 +7.4% 7.82 US$101,025
2023-03-03 2023-03-01 PlS Planned sale
3.5
Henderson Molly

CFO and CBO

Officer
2,032 -2.6%
8.53
US$17,335 		2,032 -2.6% 8.53 US$17,335
2023-03-03 2023-03-01 PlS Planned sale
3.2
Curran Terrie

President and Chief Executive

Executive Director
1,436 -0.8%
8.54
US$12,265 		1,436 -0.8% 8.54 US$12,265
2023-02-14 2023-02-13 B Purchase
3.9
Parikh Asit
Non-Executive Director
5,000 +28.6%
7.73
US$38,660 		5,000 +28.6% 7.73 US$38,660
2023-01-20 2023-01-20 S Sale
3.2
Curran Terrie

President and Chief Executive

Executive Director
5,821 -3.2%
8.20
US$47,729 		5,821 -3.2% 8.20 US$47,729
2023-01-12 2023-01-12 B Purchase
3.9
Parikh Asit
Non-Executive Director
5,000 +40.0%
7.00
US$35,000 		5,000 +40.0% 7.00 US$35,000
2022-11-23 2022-11-21 S Sale
3.5
Henderson Molly

CFO and CBO

Officer
2,159 -4.7%
9.60
US$20,726 		2,159 -4.7% 9.60 US$20,726
2022-11-23 2022-11-21 S Sale
3.2
Curran Terrie

President and Chief Executive

Executive Director
1,526 -1.8%
9.60
US$14,650 		1,526 -1.8% 9.60 US$14,650
2022-05-16 2022-05-16 B Purchase
2.5
Nabulsi Azmi

Chief Operating Officer

Officer
20,000 +2.6%
8.16
US$163,288 		20,000 +2.6% 8.16 US$163,288
2022-05-16 2022-05-13 B Purchase
3.5
Henderson Molly

CFO and CBO

Officer
6,000
0.00
US$0 		6,000 0.00 US$0
2022-05-16 2022-05-13 B Purchase
3.2
Curran Terrie

President and Chief Executive

Executive Director
20,500 +46.5%
7.41
US$151,835 		20,500 +46.5% 7.41 US$151,835
2022-05-16 2022-05-12 B Purchase
3.9
Parikh Asit
Non-Executive Director
12,500 +inf%
8.00
US$100,000 		12,500 +inf% 8.00 US$100,000
2022-03-16 2022-03-14 S Sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
18 -0.0%
19.00
US$342 		18 -0.0% 19.00 US$342
2021-11-08 2021-11-04 S Sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
1,000,000 -90.9%
20.85
US$20,850,000 		1,000,000 -90.9% 20.85 US$20,850,000
2021-11-08 2021-11-04 S Sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
1 -0.0%
19.00
US$19 		1 -0.0% 19.00 US$19
2021-10-08 2021-10-08 S Sale
3.8
Socks David A
Non-Executive Director
2,529 -0.2%
32.05
US$81,052 		2,529 -0.2% 32.05 US$81,052
2021-10-08 2021-10-07 PlS Planned sale
3.8
Socks David A
Non-Executive Director
15,471 -1.3%
32.66
US$505,343 		15,471 -1.3% 32.66 US$505,343
2021-06-29 2021-06-29 S Sale
3.8
Socks David A
Non-Executive Director
13,960 -1.1%
34.00
US$474,657 		13,960 -1.1% 34.00 US$474,657
2021-06-29 2021-06-28 S Sale
3.8
Socks David A
Non-Executive Director
156 -0.0%
35.09
US$5,474 		156 -0.0% 35.09 US$5,474
2021-06-29 2021-06-28 PlS Planned sale
3.8
Socks David A
Non-Executive Director
25,884 -2.0%
34.07
US$881,811 		25,884 -2.0% 34.07 US$881,811
2021-06-29 2021-06-28 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
370 -0.0%
35.08
US$12,980 		370 -0.0% 35.08 US$12,980
2021-06-29 2021-06-25 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
1,250 -0.1%
36.07
US$45,088 		1,250 -0.1% 36.07 US$45,088
2021-06-29 2021-06-25 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
22,881 -2.5%
35.46
US$811,360 		22,881 -2.5% 35.46 US$811,360
2021-06-25 2021-06-24 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
10,848 -1.2%
35.14
US$381,199 		10,848 -1.2% 35.14 US$381,199
2021-06-25 2021-06-23 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
200 -0.0%
35.00
US$7,000 		200 -0.0% 35.00 US$7,000
2021-06-23 2021-06-22 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
100 -0.0%
35.00
US$3,500 		100 -0.0% 35.00 US$3,500
2021-06-23 2021-06-21 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
9,294 -1.0%
35.31
US$328,171 		9,294 -1.0% 35.31 US$328,171
2021-06-21 2021-06-18 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
5,398 -0.6%
35.13
US$189,632 		5,398 -0.6% 35.13 US$189,632
2021-06-21 2021-06-17 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
3,305 -0.4%
35.08
US$115,939 		3,305 -0.4% 35.08 US$115,939
2021-06-16 2021-06-14 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
2,826 -0.3%
35.06
US$99,080 		2,826 -0.3% 35.06 US$99,080
2021-06-11 2021-06-10 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
2,102 -0.2%
35.14
US$73,864 		2,102 -0.2% 35.14 US$73,864
2021-06-11 2021-06-09 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
1,191 -0.1%
35.28
US$42,018 		1,191 -0.1% 35.28 US$42,018
2021-06-09 2021-06-08 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
100 -0.0%
35.00
US$3,500 		100 -0.0% 35.00 US$3,500
2021-06-09 2021-06-07 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
2,264 -0.2%
35.05
US$79,353 		2,264 -0.2% 35.05 US$79,353
2021-06-04 2021-06-02 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
4,300 -0.5%
35.18
US$151,274 		4,300 -0.5% 35.18 US$151,274
2021-06-02 2021-06-01 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
3,967 -0.4%
36.20
US$143,605 		3,967 -0.4% 36.20 US$143,605
2021-06-02 2021-06-01 PlS Planned sale
3.6
TAKEDA PHARMACEUTICAL CO LTD
Large shareholder
7,244 -0.8%
35.55
US$257,524 		7,244 -0.8% 35.55 US$257,524
Explore more

More insider trading research around Phathom Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America